China’s attempt at making a vaccine to fight the SARS-CoV-2, better known as Covid-19, is moving along nicely with phase two trials showing an immune response in the majority of patients.
A randomized, double-blind, placebo-controlled, trial of the vaccine known as Ad5 was conducted in the coronavirus’ home town of Wuhan, China. The vaccine was developed by CanSino Biologics. The company’s shares rose 1.74% on Tuesday and are up 183% year-to-date.
Healthy adults aged 18 years or older and who were SARS-CoV-2 infection-free were eligible to participate in the test. Some 603 volunteers were randomly assigned to receive either the vaccine in different doses, or a placebo. They did not know which one they were getting. The injections were given in mid-April.
“The phase 2 trial adds further evidence on safety and immunogenicity in a large population than the phase 1 trial,” Professor Fengcai Zhu from Jiangsu Provincial Center for Disease Control and Prevention told the People’s Daily on Tuesday. Phase three is underway.
The Lancet published this takeaway on Monday, in case you missed it, as I did:
“The Ad5-vectored Covid-19 vaccine…is safe, and induced significant immune responses in the majority of recipients after a single immunization,” the report authors wrote.
I run this site in my spare time and thoroughly enjoy giving you all positive news! If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.